Do you want to read an article? Please log in or register.
Nivolumab for Resected Stage III or IV Melanoma at 9 Years
Skin Cancer
Related content
Skin Cancer
Five-year survival after introduction of adjuvant treatment in stage III melanoma: A nationwide registry-based study
Eur J Cancer
Helgadottir H, Ny L, Ullenhag GJ, Mikiver R, Isaksson K, Olofsson Bagge R
doi: 10.1016/j.ejca.2025.116201
Skin Cancer
Predictive value of [(18)F]FDG PET/CT and index lymph node response following neoadjuvant pembrolizumab in resectable stage 3 melanoma: Real world data from the largest melanoma centres in the Netherlands
Eur J Cancer
Wilson MJ, Schurink AW, Schrage Y, Wouters MWJM, van Houdt WJ, Grunhagen DJ, van Thienen HV, van de Wiel BA, van der Hiel B, Kuijpers AMJ
doi: 10.1016/j.ejca.2026.116691
Lung, Respiratory and Thoracic Cancer
Nivolumab plus chemoradiotherapy followed by nivolumab with or without ipilimumab for untreated locally advanced stage III NSCLC: a randomized phase 3 trial
Nat Cancer
Peters S, Tan DSW, Gerber DE, Urbanic J, Ramalingam S, Yu J, Xing L, Rittmeyer A, Ciuleanu TE, de Menezes J, Kim HR, Rojas C, Syrigos K, Hayashi H, Haridass A, Cortinovis D, Bruno D, Kimmich M, Calles A, Nathani R, Pudussery G, Yang L, De Ruysscher D
doi: 10.1038/s43018-026-01161-y
Skin Cancer
10-Years of First-Line Ipilimumab and Nivolumab in Advanced Melanoma: A Single Centre Experience
Int J Cancer
Javaid A, Peres T, Schmitt AM, Larkin J
doi: 10.1002/ijc.70653
Skin Cancer
Vibostolimab coformulated with pembrolizumab versus pembrolizumab alone as adjuvant therapy for high-risk stage IIB-IV melanoma (KEYVIBE-010): a randomised, double-blind, phase 3 study
Lancet Oncol
Dummer R, Guo J, Luke JJ, Carlino MS, Schadendorf D, Khattak MA, Hauschild A, Ascierto PA, Chen Y, Shin SJ, Rutkowski P, Luo Z, Chen J, Rivalland G, Coetzee C, Ribas A, Mujika K, Markel G, Villarroel RU, Dizdar O, Caglevic C, Grebennik D, Donovan K, Krepler C, Long GV
doi: 10.1016/S1470-2045(25)00709-0
Skin Cancer
A dynamic recurrence risk prediction tool for adjuvant therapy in stage III melanoma
Eur J Cancer
Boutros A, Taylor AM, Li I, Adegoke NA, Wong T, Varey AHR, Shannon KF, Ch'ng S, Saw RPM, Pennington T, Stretch J, Spillane A, van Akkooi ACJ, Scolyer RA, Pires da Silva I, Carlino MS, Long GV, Lo SN, Menzies AM
doi: 10.1016/j.ejca.2025.115782
RECOMMENDED
Lung, Respiratory and Thoracic Cancer
Real-world 5-year outcomes with durvalumab after chemoradiotherapy in unresectable stage III NSCLC
★ 1
Recommended by
Dr. med. Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
ESMO Open
Girard N, Bar J, Baas P, Chouaid C, Christoph DC, Field JK, Fietkau R, Garassino MC, Garrido Lopez P, Gregorc V, Haakensen VD, Hiltermann TJN, Kao S, McDonald F, Mornex F, Moskovitz M, Peters S, Siva S, Solomon B, Qiao Y, Anand S, Chander P, Shcherbakova T, Diaz Perez I, Filippi AR
doi: 10.1016/j.esmoop.2026.106070
Gynecologic Cancer
Neoadjuvant chemotherapy followed by interval surgery versus primary debulking surgery in FIGO stage III-IV epithelial ovarian cancer: A systematic review and meta-analysis
Eur J Cancer
Secchi M, Signorelli M, Rulli E, Maruccio M, Di Martino G, Spadaro D, Giudice E, Turinetto M, Landoni F, Restaino S, Vizzielli G, Martinelli F, Lorusso D
doi: 10.1016/j.ejca.2025.116116
RECOMMENDED
Lung, Respiratory and Thoracic Cancer
Definition of resectable stage III non-small cell lung cancer: A systematic review from EORTC lung cancer group
★ 2
Recommended by
Dr. med. Martin Frey, Faculty Member
★ 2
Recommended by
Dr Marcus Hesse, Faculty Member
Lung Cancer
Xenophontos E, Giaj Levra N, Durieux V, van Geffen WH, Grisay G, De la Pinta Alonso C, Arasanz H, Prisciandaro E, Ferrara R, Derks J, Von der Thusen J, Dickhoff C, Brandão M, Faivre-Finn C, Edwards J, Ruysscher D, Remon J, Dingemans AC, Berghmans T
doi: 10.1016/j.lungcan.2025.108671